Purchase this article with an account.
K. M. Narayana, A. Bosjolie, S. Dorairaj, S. Kedhar, P. Latkany, A. Ali, C. Samson; Chronic Cystoid Macular Edema (CME) Secondary to Uveitis. Invest. Ophthalmol. Vis. Sci. 2009;50(13):1542.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To study the clinical characteristics of CME, with specific reference to factors related to reversibility.
Retrospective chart review of patients having a diagnosis of CME, as determined clinically, angiographically or by Optical Coherence tomography between 2001 through 2008, at the private practices of 2 uveitis subspecialists.
98 eyes of 49 persons were studied. The mean age of persons was 46.16 ± 15.80 years(median 46 years, range 5 to 80 years); 38 (77.56%) were females. The Mean age at diagnosis of uveitis was 42.37 ± 16.26 (median 42 years, range 6 to 75 years), and at diagnosis of CME was 44.46 ± 15.63 (median 45 years, range 6 to 82 years). The mean duration of past uveitis was 4.22 ± 5.48 years, median= 2 years, range < 1 year to 28 years. At 6 months after initial diagnosis, 26 eyes had irreversible CME and 39 eyes had reversible CME; 12 eyes had recurrent CME. Reversible CME was associated with past steroid drop therapy (fishers exact p value=0.009) but was not associated with other systemic illnesses or other past treatment for CME. 50% of eyes had normal vision (upto 20/60) at baseline and 14.29% eyes had severe vision loss (< 20/200). At 6 months follow up 59.42% eyes normal vision and 17.39% eyes had severe vision loss; severe vision loss was significantly associated with irreversible CME.From data available from 45 subjects, the duration of uveitis was not significantly different between irreversible ( mean days 2093.11, SD 2078.81, ) or reversible (mean days 1157.65, SD 2137.22) p=0.15.
Irreversible CME is significantly associated with severe vision loss. Duration of uveitis doesn’t seem to directly influence the reversibility of CME. Reversibility appears to be related more to the severity rather than the duration of the disease.
This PDF is available to Subscribers Only